医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
10期
81-81,82
,共2页
辅助性治疗%艾迪莎%溃疡性结肠炎%临床疗效
輔助性治療%艾迪莎%潰瘍性結腸炎%臨床療效
보조성치료%애적사%궤양성결장염%림상료효
Adjuvant treatment%Etiasa%Ulcerative colitis%Clinical curative effect
目的:探索艾迪莎辅助治疗溃疡性结肠炎的临床疗效。方法:将我院收治的溃疡性结肠炎患者120例,随机分组为对照组和实验组,每组60例患者。对照组我们采用常规治疗药物进行治疗,实验组在常规用药的基础上加用艾迪莎。对比不同时间段内不良反应和并发症情况。结果:实验组组2个月、4个月和8个月三个时间节点临床症状缓解率较对照组的显著升高,(P<0.01)差异具有明显的统计学意义。实验组2个月、4个月和8个月的淋巴结吸收率显著高于对照组的,(P<0.05)差异具有统计学意义。结论:常规药物治疗联合艾迪莎辅助性治疗,可有效的提高溃疡性结肠炎的症状缓解率和淋巴结吸收率。
目的:探索艾迪莎輔助治療潰瘍性結腸炎的臨床療效。方法:將我院收治的潰瘍性結腸炎患者120例,隨機分組為對照組和實驗組,每組60例患者。對照組我們採用常規治療藥物進行治療,實驗組在常規用藥的基礎上加用艾迪莎。對比不同時間段內不良反應和併髮癥情況。結果:實驗組組2箇月、4箇月和8箇月三箇時間節點臨床癥狀緩解率較對照組的顯著升高,(P<0.01)差異具有明顯的統計學意義。實驗組2箇月、4箇月和8箇月的淋巴結吸收率顯著高于對照組的,(P<0.05)差異具有統計學意義。結論:常規藥物治療聯閤艾迪莎輔助性治療,可有效的提高潰瘍性結腸炎的癥狀緩解率和淋巴結吸收率。
목적:탐색애적사보조치료궤양성결장염적림상료효。방법:장아원수치적궤양성결장염환자120례,수궤분조위대조조화실험조,매조60례환자。대조조아문채용상규치료약물진행치료,실험조재상규용약적기출상가용애적사。대비불동시간단내불량반응화병발증정황。결과:실험조조2개월、4개월화8개월삼개시간절점림상증상완해솔교대조조적현저승고,(P<0.01)차이구유명현적통계학의의。실험조2개월、4개월화8개월적림파결흡수솔현저고우대조조적,(P<0.05)차이구유통계학의의。결론:상규약물치료연합애적사보조성치료,가유효적제고궤양성결장염적증상완해솔화림파결흡수솔。
Objective Explore etiasa auxiliary clinical curative effect for the treatment of ulcerative colitis. Methods Will our hospital 120 cases of patients with ulcerative colitis, randomly grouped into control group and experimental group, 60 cases in each group. Control group we adopt conventional drug treatment, the experimental group on the basis of conventional drugs used etiasa. Results Experiment way 2 months, 4 months and 8 months three time node a significant rise in clinical symptom remission rate than the control group, (P < 0.01) difference has the obvious statistical significance. Experimental group 2 months, 4 months and 8 months of lymph node of absorption rate is significantly higher than the control group, (P < 0.05) difference is statistically significant. Conclusions Routine drug treatment combined etiasa auxiliary treatment, which can effectively improve the symptoms of ulcerative colitis absorption rate and lymph nodes.